NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis $8.68 -0.36 (-3.98%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$8.68 0.00 (0.00%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Contineum Therapeutics Stock (NASDAQ:CTNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Contineum Therapeutics alerts:Sign Up Key Stats Today's Range$8.50▼$9.1150-Day Range$7.08▼$14.8252-Week Range$6.72▼$17.78Volume369,212 shsAverage Volume562,296 shsMarket Capitalization$340.86 millionP/E RatioN/ADividend YieldN/APrice Target$21.40Consensus RatingHold Company Overview Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions. Contineum’s programs are in clinical development, and the company does not currently offer approved medicines for sale. Its work centers on advancing potential therapies through clinical testing for conditions with significant unmet medical needs.AI Generated. May Contain Errors. Read More Contineum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCTNM MarketRank™: 1.710325710325 of 5 starsContineum Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 692nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingContineum Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialContineum Therapeutics has a consensus price target of $21.40, representing about 146.5% upside from its current price of $8.68.Amount of Analyst CoverageContineum Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Contineum Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Contineum Therapeutics are expected to decrease in the coming year, from ($1.78) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Contineum Therapeutics is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Contineum Therapeutics is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContineum Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.67% of the float of Contineum Therapeutics has been sold short.Short Interest Ratio / Days to CoverContineum Therapeutics has a short interest ratio ("days to cover") of 4.23.Change versus previous monthShort interest in Contineum Therapeutics has recently increased by 1.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContineum Therapeutics does not currently pay a dividend.Dividend GrowthContineum Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentContineum Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.90% of the stock of Contineum Therapeutics is held by insiders.Percentage Held by InstitutionsContineum Therapeutics has minimal institutional ownership at this time.Read more about Contineum Therapeutics' insider trading history. Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTNM Stock News HeadlinesContineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street ZenNovember 14, 2026 | americanbankingnews.comQureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical TrialNovember 9, 2026 | finance.yahoo.comPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 21 at 1:00 AM | Base Camp Trading (Ad)Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical TrialNovember 9, 2026 | businesswire.comContineum Therapeutics Reports Third-Quarter 2026 Financial ResultsNovember 3, 2026 | finance.yahoo.comContineum Therapeutics, Inc. Class A (CTNM) Stock Forecast & Price TargetNovember 3, 2026 | tipranks.comContineum Therapeutics, Inc. Class A (CTNM) AI Stock AnalysisNovember 3, 2026 | tipranks.comContineum Therapeutics to Present at the Stifel 2026 Healthcare ConferenceOctober 29, 2026 | finance.yahoo.comSee More Headlines CTNM Stock Analysis - Frequently Asked Questions How have CTNM shares performed this year? Contineum Therapeutics' stock was trading at $11.43 at the beginning of 2026. Since then, CTNM shares have decreased by 24.1% and is now trading at $8.68. How were Contineum Therapeutics' earnings last quarter? Contineum Therapeutics, Inc. (NASDAQ:CTNM) released its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.04. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $117 million in an IPO on Friday, April 5th 2024. The company issued 6,875,000 shares at a price of $16.00-$18.00 per share. Who are Contineum Therapeutics' major shareholders? Top institutional shareholders of Contineum Therapeutics include Versant Venture Management LLC (3.44%), State Street Corp (2.15%), Goldman Sachs Group Inc. (1.92%) and Integral Health Asset Management LLC (0.88%). How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/03/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CTNM's financial health is in the Yellow zone, according to TradeSmith. CTNM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CTNM Previous SymbolNASDAQ:CTNM CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees51Year Founded2017Price Target and Rating Average Price Target for Contineum Therapeutics$21.40 High Price Target$30.00 Low Price Target$14.00 Potential Upside/Downside+146.5%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-25.48% Return on Assets-24.28% Debt Debt-to-Equity RatioN/A Current Ratio31.11 Quick Ratio31.11 Sales & Book Value Annual Sales$50 million Price / Sales6.82 Cash FlowN/A Price / Cash FlowN/A Book Value$6.25 per share Price / Book1.39Miscellaneous Outstanding Shares39,270,000Free Float36,164,000Market Cap$340.86 million OptionableOptionable Beta1.07 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:CTNM) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.